The inflammatory marker YKL-40 is elevated in cerebrospinal fluid from patients with Alzheimer's but not Parkinson's disease or dementia with Lewy bodies

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Wennström, Malin ^a   Surova, Yulia ^a,b   Hall, Sara ^a,b   Nilsson, Christer ^a,b   Minthon, Lennart ^a,b   Hansson, Oskar ^a,b   Nielsen, Henrietta M ^a,c  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; EOTAXIN; EOTAXIN 3; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOPROTEIN; INTERLEUKIN 8; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 4; TAU PROTEIN; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG; YKKL 40 PROTEIN; ADIPOCYTOKINE; BIOLOGICAL MARKER; CHEMOKINE; CHI3L1 PROTEIN, HUMAN; CHITINASE 3 LIKE PROTEIN 1; LECTIN; NERVE PROTEIN;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; PROTEIN ANALYSIS; SENSITIVITY AND SPECIFICITY; CEREBROSPINAL FLUID; DEMENTIA; IMMUNOLOGY;

ADIPOKINES; AGE FACTORS; ALZHEIMER DISEASE; BIOMARKERS; CHEMOKINES; CHITINASE-3-LIKE PROTEIN 1; DEMENTIA; HUMANS; LECTINS; LEWY BODY DISEASE; NERVE TISSUE PROTEINS; PARKINSON DISEASE;

EID: 84942911159     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135458     Document Type: Article

References (46)

1. Thies W, Bleiler L. 2013 Alzheimer's disease facts and figures. Alzheimers Dement. 2013; 9(2):208-45. Epub 2013/03/20. doi: 10.1016/j.jalz.2013.02.003 PMID: 23507120.
2. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):270-9. Epub 2011/04/26. doi: 10.1016/j.jalz.2011.03.008 PMID: 21514249; PubMed Central PMCID: PMC3312027.
3. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):263-9. Epub 2011/04/26. doi: 10.1016/j.jalz.2011.03.005 PMID: 21514250; PubMed Central PMCID: PMC3312024.
4. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7 (3):280-92. Epub 2011/04/26. doi: 10.1016/j.jalz.2011.03.003 PMID: 21514248; PubMed Central PMCID: PMC3220946.
5. Atkinson AJ, Colburn WA, DeGruttola WG, DeMets DL, Downing GJ, Hoth DF, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69 (3):89-95. Epub 2001/03/10. doi: 10.1067/mcp.2001.113989 PMID: 11240971.
6. Rosen C, Hansson O, Blennow K, Zetterberg H. Fluid biomarkers in Alzheimer's disease-current concepts. Mol Neurodegener. 2013; 8:20. Epub 2013/06/27. doi: 10.1186/1750-1326-8-20 PMID: 23800368; PubMed Central PMCID: PMC3691925.
7. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry. 2010; 68(10):903-12. Epub 2010/11/03. S0006-3223(10)00890-5 [pii] doi: 10.1016/j.biopsych.2010.08.025 PMID: 21035623; PubMed Central PMCID: PMC3011944.
8. Olsson B, Hertze J, Lautner R, Zetterberg H, Nagga K, Hoglund K, et al. Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia. J Alzheimers Dis. 2013; 33 (1):45-53. Epub 2012/08/15. doi: 10.3233/JAD-2012-120787 PMID: 22890100.
9. Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One. 2011; 6 (1):e16032. Epub 2011/01/26. doi: 10.1371/journal.pone.0016032 PMID: 21264269; PubMed Central PMCID: PMC3020224.
10. Wildsmith KR, Schauer SP, Smith AM, Arnott D, Zhu Y, Haznedar J, et al. Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics. Mol Neurodegener. 2014; 9(1):22. Epub 2014/06/07. doi: 10.1186/1750-1326-9-22 PMID: 24902845.
11. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev. 2006; 15(2):194-202. Epub 2006/02/24. doi: 10.1158/1055-9965.EPI-05-0011 PMID: 16492905.
12. Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation. 2010; 7:34. Epub 2010/06/15. doi: 10.1186/1742-2094-7-34 PMID: 20540736; PubMed Central PMCID: PMC2892443.
13. Bonneh-Barkay D, Zagadailov P, Zou H, Niyonkuru C, Figley M, Starkey A, et al. YKL-40 expression in traumatic brain injury: an initial analysis. J Neurotrauma. 2010; 27(7):1215-23. Epub 2010/05/22. doi: 10.1089/neu.2010.1310 PMID: 20486806; PubMed Central PMCID: PMC2942903.
14. Nielsen HM, Hall S, Surova Y, Nagga K, Nilsson C, Londos E, et al. Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies. J Alzheimers Dis. 2014; 40(2):343-50. Epub 2014/01/23. doi: 10.3233/JAD-132246 PMID: 24448788.
15. Wennstrom M, Surova Y, Hall S, Nilsson C, Minthon L, Bostrom F, et al. Low CSF levels of both alphasynuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS One. 2013; 8(1):e53250. Epub 2013/01/12. doi: 10.1371/journal.pone.0053250 PMID: 23308173; PubMed Central PMCID: PMC3540093.
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34(7):939-44. PMID: 6610841.
17. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005; 65(12):1863-72. PMID: 16237129.
18. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999; 56(1):33-9. Epub 1999/01/29. PMID: 9923759.
19. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010; 6(3):131-44. Epub 2010/02/17. nrneurol.2010.4 [pii] doi: 10.1038/nrneurol.2010.4 PMID: 20157306.
20. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011; 10(3):230-40. Epub 2011/02/15. S1474-4422(11)70014-X [pii] doi: 10.1016/S1474-4422(11)70014-X PMID: 21317042.
21. Tateno F, Sakakibara R, Kawai T, Kishi M, Murano T. Alpha-synuclein in the Cerebrospinal Fluid Differentiates Synucleinopathies (Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy) From Alzheimer Disease. Alzheimer Dis Assoc Disord. in press. Epub 2011/11/01. doi: 10.1097/WAD.0b013e31823899cc PMID: 22037599.
22. Wennstrom M, Londos E, Minthon L, Nielsen HM. Altered CSF orexin and alpha-synuclein levels in dementia patients. J Alzheimers Dis. 2012; 29(1):125-32. Epub 2011/12/31. doi: 10.3233/JAD-2012-111655 PMID: 22207004.
23. Bonneh-Barkay D, Bissel SJ, Kofler J, Starkey A, Wang G, Wiley CA. Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation. Brain Pathol. 2012; 22 (4):530-46. Epub 2011/11/15. doi: 10.1111/j.1750-3639.2011.00550.x PMID: 22074331; PubMed Central PMCID: PMC3557465.
24. Fiandaca MS, Mapstone ME, Cheema AK, Federoff HJ. The critical need for defining preclinical biomarkers in Alzheimer's disease. Alzheimers Dement. 2014; 10(3 Suppl):S196-212. Epub 2014/06/14. doi: 10.1016/j.jalz.2014.04.015 PMID: 24924671.
25. Olsson B, Constantinescu R, Holmberg B, Andreasen N, Blennow K, Zetterberg H. The glial marker YKL-40 is decreased in synucleinopathies. Mov Disord. 2013; 28(13):1882-5. Epub 2013/07/13. doi: 10.1002/mds.25589 PMID: 23847144.
26. Mattsson N, Tabatabaei S, Johansson P, Hansson O, Andreasson U, Mansson JE, et al. Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility. Neuromolecular Med. 2011; 13(2):151-9. Epub 2011/05/14. doi: 10.1007/s12017-011-8147-9 PMID: 21567187.
27. Jesse S, Steinacker P, Cepek L, von Arnim CA, Tumani H, Lehnert S, et al. Glial fibrillary acidic protein and protein S-100B: different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer's disease and Creutzfeldt-Jakob disease. J Alzheimers Dis. 2009; 17(3):541-51. Epub 2009/05/13. 25G1G0U532157316 [pii] doi: 10.3233/JAD-2009-1075 PMID: 19433893.
28. Yang Z, Wang KK. Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci. 2015; 38(6):364-74. Epub 2015/05/16. doi: 10.1016/j.tins.2015.04.003 PMID: 25975510.
29. Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Venturelli E, Pijnenburg YA, et al. Intrathecal chemokine levels in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2006; 66 (1):146-7. Epub 2006/01/13. doi: 10.1212/01.wnl.0000191324.08289.9d PMID: 16401871.
30. Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Bouwman F, Venturelli E, et al. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol. 2006; 63 (4):538-43. Epub 2006/04/12. doi: 10.1001/archneur.63.4.538 PMID: 16606766.
31. Westin K, Buchhave P, Nielsen H, Minthon L, Janciauskiene S, Hansson O. CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. PLoS One. 2012; 7(1): e30525. Epub 2012/02/04. doi: 10.1371/journal.pone.0030525 PMID: 22303443; PubMed Central PMCID: PMC3268759.
32. Shimizu F, Nishihara H, Sano Y, Takeshita Y, Takahashi S, Maeda T, et al. Markedly increased IP-10 production by blood-brain barrier in neuromyelitis optica. PLoS One. 2015; 10(3):e0122000. Epub 2015/03/27. doi: 10.1371/journal.pone.0122000 PMID: 25811465; PubMed Central PMCID: PMC4374747.
33. Stanimirovic D, Satoh K. Inflammatory mediators of cerebral endothelium: a role in ischemic brain inflammation. Brain Pathol. 2000; 10(1):113-26. Epub 2000/02/11. PMID: 10668901.
34. Liu C, Cui G, Zhu M, Kang X, Guo H. Neuroinflammation in Alzheimer's disease: chemokines produced by astrocytes and chemokine receptors. Int J Clin Exp Pathol. 2014; 7(12):8342-55. Epub 2015/02/13. PMID: 25674199; PubMed Central PMCID: PMC4314046.
35. Guijarro-Munoz I, Compte M, Alvarez-Cienfuegos A, Alvarez-Vallina L, Sanz L. Lipopolysaccharide activates Toll-like receptor 4 (TLR4)-mediated NF-kappaB signaling pathway and proinflammatory response in human pericytes. J Biol Chem. 2014; 289(4):2457-68. Epub 2013/12/07. doi: 10.1074/jbc.M113.521161 PMID: 24307174; PubMed Central PMCID: PMC3900988.
36. Jansson D, Rustenhoven J, Feng S, Hurley D, Oldfield RL, Bergin PS, et al. A role for human brain pericytes in neuroinflammation. J Neuroinflammation. 2014; 11:104. Epub 2014/06/13. doi: 10.1186/1742-2094-11-104 PMID: 24920309; PubMed Central PMCID: PMC4105169.
37. Rock RB, Gekker G, Hu S, Sheng WS, Cheeran M, Lokensgard JR, et al. Role of microglia in central nervous system infections. Clin Microbiol Rev. 2004; 17(4):942-64, table of contents. Epub 2004/10/19. doi: 10.1128/CMR.17.4.942-964.2004 PMID: 15489356; PubMed Central PMCID: PMC523558.
38. Balabanov R, Strand K, Goswami R, McMahon E, Begolka W, Miller SD, et al. Interferon-gamma-oligodendrocyte interactions in the regulation of experimental autoimmune encephalomyelitis. J Neurosci. 2007; 27(8):2013-24. Epub 2007/02/23. doi: 10.1523/JNEUROSCI.4689-06.2007 PMID: 17314297.
39. Ramesh G, Benge S, Pahar B, Philipp MT. A possible role for inflammation in mediating apoptosis of oligodendrocytes as induced by the Lyme disease spirochete Borrelia burgdorferi. J Neuroinflammation. 2012; 9:72. Epub 2012/04/25. doi: 10.1186/1742-2094-9-72 PMID: 22524232; PubMed Central PMCID: PMC3416675.
40. Coughlan CM, McManus CM, Sharron M, Gao Z, Murphy D, Jaffer S, et al. Expression of multiple functional chemokine receptors and monocyte chemoattractant protein-1 in human neurons. Neuroscience. 2000; 97(3):591-600. Epub 2000/06/01. PMID: 10828541.
41. Wang X, Ellison JA, Siren AL, Lysko PG, Yue TL, Barone FC, et al. Prolonged expression of interferoninducible protein-10 in ischemic cortex after permanent occlusion of the middle cerebral artery in rat. J Neurochem. 1998; 71(3):1194-204. Epub 1998/08/29. PMID: 9721745.
42. Thompson WL, Van Eldik LJ. Inflammatory cytokines stimulate the chemokines CCL2/MCP-1 and CCL7/MCP-3 through NFkB and MAPK dependent pathways in rat astrocytes [corrected]. Brain Res. 2009; 1287:47-57. Epub 2009/07/07. doi: 10.1016/j.brainres.2009.06.081 PMID: 19577550; PubMed Central PMCID: PMC2725204.
43. Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M. Multiple control of interleukin-8 gene expression. J Leukoc Biol. 2002; 72(5):847-55. Epub 2002/11/14. PMID: 12429706.
44. Greten FR, Arkan MC, Bollrath J, Hsu LC, Goode J, Miething C, et al. NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell. 2007; 130(5):918-31. Epub 2007/09/07. doi: 10.1016/j.cell.2007.07.009 PMID: 17803913; PubMed Central PMCID: PMC2134986.
45. Rehli M, Niller HH, Ammon C, Langmann S, Schwarzfischer L, Andreesen R, et al. Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem. 2003; 278 (45):44058-67. Epub 2003/08/23. doi: 10.1074/jbc.M306792200 PMID: 12933821.
46. Antonell A, Mansilla A, Rami L, Llado A, Iranzo A, Olives J, et al. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease. J Alzheimers Dis. 2014; 42(3):901-8. Epub 2014/07/16. doi: 10.3233/JAD-140624 PMID: 25024322.